Technology | December 11, 2012

Devicor Announces FDA Approves Mammotome revolve Biopsy System

Featuring patented DualVac technology and patented specimen management system

Mammotome Revolve Breast biopsy systems/accessories

December 11, 2012 — Devicor Medical Products Inc. (Devicor) announced that the U.S. Food and Drug Administration (FDA) has approved Mammotome revolve, a dual vacuum-assisted biopsy system, for use on patients.

Mammotome revolve is the next generation breast biopsy system, leveraging the clinician and pathologist valued benefits of the original Mammotome system to provide high quality tissue specimens, now enhanced in the new system with innovative features to provide further procedural efficiency and ease of use. Mammotome revolve features an advanced specimen management system capable of collecting and organizing high quality individual tissue samples in numbered, specimen radiograph and pathology-ready chambers that preserve tissue integrity. The system also features patented DualVac vacuum technology that gives clinicians the ability to secure larger contiguous tissue samples.

These features in combination with a physician controlled variable aperture allow clinicians to confirm or adjust sample acquisition in response to procedural situations to confidently access and acquire challenging lesions. An additional benefit is the efficiency of pre-biopsy planning time.

"Mammotome has always given great quality samples — that's the most important thing," said Teri-Ann Gizienski of Magee-Womens Hospital of Cranberry. "Mammotome revolve takes efficiency to a whole new level while giving beautiful samples. It's able to easily sample dense breast tissue, and the speed is remarkable. I was able to capture three great tissue samples from the same location, which was nearly impossible before. The collection system keeps the samples organized and so easy to manage, even for the specimen radiograph. This is ideal for physicians and facilities who are very busy, but who still want great tissue. It's a phenomenal system."

Devicor President and CEO Tom Daulton believes that larger core samples and reduced procedural time mean a faster and less traumatic experience for the patient, and samples coming back from pathology are likely to have a more definitive diagnosis. Says Daulton, "Mammotome revolve uses breakthrough technology that offers peace of mind for clinicians and the patients they treat.  With this new product, clinicians can be confident that patients are more likely to have a less painful and traumatic experience."

"The success of our recent new product innovations demonstrates why Mammotome is the undisputed worldwide leader in the field of vacuum assisted breast biopsy," says Daulton.

In 2011, more than 1.4 million women in the United States underwent a biopsy procedure with approximately 40 percent of those undergoing vacuum-assisted breast biopsies. VAB procedures are growing in popularity with clinicians because they are less invasive than surgery. Over four million women worldwide have had successful breast biopsies using the Mammotome Biopsy System since 1995.

Mammotome revolve is currently available in limited market release in the United States, Canada and Europe. Mammotome revolve is expected to be available in full market release by spring of 2013.

For more information: www.devicormedical.com, www.mammotome.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Breast imaging technologies have seen a rapid evolution.

Breast imaging technologies have seen a rapid evolution.

Feature | Women's Health | June 05, 2018 | By Jeff Zagoudis
Breast imaging technologies have evolved rapidly in the last two decades to help physicians detect breast cancers at
Breast Cancer Survivors Not Getting Recommended Number of Mammograms Post-Surgery
News | Mammography | May 24, 2018
Breast cancer survivors are not getting the recommended level of screening post-surgery, according to a newly-published...
Overlay Init